The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?
Abstract
Antiviral agents for the treatment of influenza are urgently needed to circumvent the limitations of current drugs in several critical areas: high frequencies of resistance to M2 inhibitors among currently circulating strains and variable frequencies of resistance to oseltamivir among A(H1N1) strains, limited efficacy of treatment and treatment-emergent antiviral resistance in cases of avian influenza A(H5N1) illness in humans, and lack of parenteral agents for seriously ill patients. Two neuraminidase inhibitors (NAIs), zanamivir and peramivir, have undergone or are undergoing clinical trials for use by intravenous or intramuscular administration, and one long-acting NAI, designated CS-8958, is under study for use by inhalation. Advances in understanding the mechanisms involved in influenza virus replication have revealed a number of potential targets that might be exploited in the development of new agents. Among these agents are T-705, a polymerase inhibitor, and DAS181, an attachment inhibitor. Combination therapy with currently available agents is supported by data from animal models but has received limited clinical study to date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,011
Avian Influenza A (H5N1) Infection in Humans
(2005) · New England Journal of Medicine · doi:10.1056/nejmra052211 · Cited by 1,285
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J. D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa054512 · Cited by 901
Update on Avian Influenza A (H5N1) Virus Infection in Humans
(2008) · New England Journal of Medicine · doi:10.1056/nejmra0707279 · Cited by 860
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 786
Self-citationBright, R. A., Medina, M.-J., Xu, X., Perez-Oronoz, G., Wallis, T. R., Davis, X. M., Povinelli, L., Cox, N. J., & Klimov, A. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67338-2 · Cited by 725
Oral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Self-citationAntiviral agents active against influenza A viruses
De Clercq, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2175 · Cited by 668
Mechanism of Action of T-705 against Influenza Virus
Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., & Shiraki, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.981-986.2005 · Cited by 546
Deyde, V. M., Xu, X., Bright, R. A., Shaw, M., Smith, C. B., Zhang, Y., Shu, Y., Gubareva, L. V., Cox, N. J., & Klimov, A. I. (2007) · The Journal of Infectious Diseases · doi:10.1086/518936 · Cited by 543
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.977-981.2002 · Cited by 501
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
Ward, P., Small, I., Smith, J., Suter, P., & Dutkowski, R. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki018 · Cited by 428
Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in Families
Hayden, F. G., Belshe, R. B., Clover, R. D., Hay, A. J., Oakes, M. G., & Soo, W. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912213212502 · Cited by 416
Self-citationTreatment with Convalescent Plasma for Influenza A (H5N1) Infection
Zhou, B., Zhong, N., & Guan, Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070359 · Cited by 406
Antiviral Therapy and Outcomes of Influenza Requiring Hospitalization in Ontario, Canada
McGeer, A., Green, K. A., Plevneshi, A., Shigayeva, A., Siddiqi, N., Raboud, J., Low, D. E., & Toronto Invasive Bacterial Diseases Network (2007) · Clinical Infectious Diseases · doi:10.1086/523584 · Cited by 398
Nichols, W. G., Guthrie, K. A., Corey, L., & Boeckh, M. (2004) · Clinical Infectious Diseases · doi:10.1086/425004 · Cited by 377
Chemaly, R. F., Ghosh, S., Bodey, G. P., Rohatgi, N., Safdar, A., Keating, M. J., Champlin, R. E., Aguilera, E. A., Tarrand, J. J., & Raad, I. I. (2006) · Medicine · doi:10.1097/01.md.0000232560.22098.4e · Cited by 329
Recovery of Drug‐Resistant Influenza Virus from Immunocompromised Patients: A Case Series
Ison, M. G., Gubareva, L. V., Atmar, R. L., Treanor, J., & Hayden, F. G. (2006) · The Journal of Infectious Diseases · doi:10.1086/500465 · Cited by 261
Self-citationSialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection
Malakhov, M. P., Aschenbrenner, L. M., Smee, D. F., Wandersee, M. K., Sidwell, R. W., Gubareva, L. V., Mishin, V. P., Hayden, F. G., Kim, D. H., Ing, A., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1470-1479.2006 · Cited by 233
Self-citationCurrent and future antiviral therapy of severe seasonal and avian influenza
Beigel, J., & Bray, M. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2008.01.003 · Cited by 232
Cass, L. M. R., Efthymiopoulos, C., & Bye, A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936001-00001 · Cited by 227
Emergence of Influenza B Viruses With Reduced Sensitivity to Neuraminidase Inhibitors
Hatakeyama, S., Sugaya, N., Ito, M., Yamazaki, M., Ichikawa, M., Kimura, K., Kiso, M., Shimizu, H., Kawakami, C., Koike, K., et al. (2007) · JAMA · doi:10.1001/jama.297.13.1435 · Cited by 216
Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors
Mishin, V. P., Hayden, F. G., & Gubareva, L. V. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4515-4520.2005 · Cited by 216
Self-citationProphylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 Influenza
Simmons, C. P., Bernasconi, N. L., Suguitan, A. L., Mills, K., Ward, J. M., Chau, N. V. V., Hien, T. T., Sallusto, F., Ha, D. Q., Farrar, J., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040178 · Cited by 208
Wetherall, N. T., Trivedi, T., Zeller, J., Hodges-Savola, C., McKimm-Breschkin, J. L., Zambon, M., & Hayden, F. G. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.2.742-750.2003 · Cited by 207
Self-citationGubareva, L. V., Webster, R. G., & Hayden, F. G. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3403-3408.2001 · Cited by 203
Self-citationChildren With Influenza A Infection: Treatment With Rimantadine
Hall, C. B., Dolin, R., Gala, C. L., Markovitz, D. M., Zhang, Y. Q., Madore, P. H., Disney, F. A., Talpey, W. B., Green, J. L., Francis, A. B., et al. (1987) · Pediatrics · doi:10.1542/peds.80.2.275 · Cited by 196
Schünemann, H. J., Hill, S. R., Kakad, M., Bellamy, R., Uyeki, T. M., Hayden, F. G., Yazdanpanah, Y., Beigel, J., Chotpitayasunondh, T., Del Mar, C., et al. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70684-3 · Cited by 178
Self-citationEnglund, J. A., Champlin, R. E., Wyde, P. R., Kantarjian, H., Atmar, R. L., Tarrand, J., Yousuf, H., Regnery, H., Klimov, A. I., Cox, N. J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516358 · Cited by 162
Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice
Sidwell, R. W., Barnard, D. L., Day, C. W., Smee, D. F., Bailey, K. W., Wong, M., Morrey, J. D., & Furuta, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01051-06 · Cited by 161
Anti-influenza virus activity of peramivir in mice with single intramuscular injection
Bantia, S., Arnold, C., Parker, C. D., Upshaw, R., & Chand, P. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.10.002 · Cited by 149
Abdel-Ghafar, A.-N., Hayden, F. G., Hiền, N. Đ., de Jong, M. D., Shindo, N., Soeroso, S., & Uyeki, T. M. (2008) · Cited by 149
Self-citationRecovery of drug-resistant influenza A virus during therapeutic use of rimantadine
Hayden, F. G., Sperber, S. J., Belshe, R. B., Clover, R. D., Hay, A. J., & Pyke, S. D. M. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.9.1741 · Cited by 148
Self-citationBelser, J. A., Lu, X., Szretter, K. J., Jin, X., Aschenbrenner, L. M., Lee, A., HAWLEY, S. B., Kim, D. H., Malakhov, M. P., Yu, M., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/522609 · Cited by 143
Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice
Ilyushina, N. A., Hoffmann, E., Salomon, R., Webster, R. G., & Govorkova, E. A. (2007) · Antiviral Therapy · doi:10.1177/135965350701200302 · Cited by 142
Calfee, D. P., Peng, A., Cass, L., Lobo, M., & Hayden, F. G. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1616 · Cited by 135
Self-citationSafety and Efficacy of Nebulized Zanamivir in Hospitalized Patients with Serious Influenza
NIAID Collaborative Antiviral Study Group, Ison, M. G., Gnann, J. W., Nagy-Agren, S. E., Treanor, J. J., Payá, C. V., Steigbigel, R. T., Elliott, M. J., Weiss, H. L., & Hayden, F. G. (2003) · Antiviral Therapy · doi:10.1177/135965350300800301 · Cited by 118
Self-citationIlyushina, N. A., Hay, A. J., Yılmaz, N., Boon, A. C. M., Webster, R. G., & Govorkova, E. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01579-07 · Cited by 117
Factors Associated with Early Hospital Discharge of Adult Influenza Patients
Lee, N. L. S., Chan, P. K. S., Choi, K., Lui, G. C.-Y., Wong, B. C. K., Cockram, C. S., Hui, D. S. C., Lai, R. W. M., Tang, J. W.-T., & Sung, J. J. �. (2007) · Antiviral Therapy · doi:10.1177/135965350701200408 · Cited by 114
Whitley, R. J., & Monto, A. S. (2006) · The Journal of Infectious Diseases · doi:10.1086/507548 · Cited by 103
Strategies of Development of Antiviral Agents Directed Against Influenza Virus Replication
Hsieh, H., & Hsu, J. T.-A. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207782794248 · Cited by 102
Use of Oseltamivir to control influenza complications after bone marrow transplantation
Machado, C. M., Boas, L. S. V., Mendes, A. V. A., da Rocha, I. F., Sturaro, D., Dulley, F. L., & Pannuti, C. M. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704534 · Cited by 99
Antivirals for influenza: Historical perspectives and lessons learned
Hayden, F. G. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.05.016 · Cited by 94
Self-citationKawai, N., Ikematsu, H., Iwaki, N., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/429241 · Cited by 92
Vu, D., Peck, A. J., Nichols, W. G., Varley, C. D., Englund, J. A., Corey, L., & Boeckh, M. (2007) · Clinical Infectious Diseases · doi:10.1086/518985 · Cited by 83
Macdonald, S. J. F., Watson, K. G., Cameron, R., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4542-4549.2004 · Cited by 82
Taylor, W. R. J., Thinh, B. N., Anh, G. T., Horby, P., Wertheim, H. F. L., Lindegårdh, N., de Jong, M. D., Stepniewska, K., Hanh, T. T., Hiền, N. Đ., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003410 · Cited by 75
Successful treatment of avian influenza with convalescent plasma.
Kong, L.-B., & Zhou, B. P. (2006) · PubMed · Cited by 73
Yun, N. E., Linde, N. S., Zacks, M. A., et al. (2008) · Virology · doi:10.1016/j.virol.2007.12.029 · Cited by 69
Treatment of influenza with neuraminidase inhibitors: virological implications
Roberts, N. A. (2001) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2001.1002 · Cited by 63
John F. Enders Lecture 2006: Antivirals for Influenza
Ong, A., & Hayden, F. G. (2007) · The Journal of Infectious Diseases · doi:10.1086/518939 · Cited by 60
Self-citationOral ribavirin treatment of influenza A and B
Stein, D. S., Creticos, C. M., Jackson, G. G., Bernstein, J. M., Hayden, F. G., Schiff, G. M., & Bernstein, D. I. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.8.1285 · Cited by 59
Self-citationHayden, F. G., Schlepushkin, A. N., & Pushkarskaya, N. L. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.1.53 · Cited by 56
Self-citationLee, N. L. S., Cockram, C. S., Chan, P. K. S., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/533477 · Cited by 53
Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection.
Hayden, F. G., Sable, C. A., Connor, J. D., & Lane, J. (1996) · PubMed · Cited by 46
Self-citationStittelaar, K. J., Tisdale, M., vanAmerongen, G., VANLAVIEREN, R., Pistoor, F. H. M., Simon, J. H., & Osterhaus, A. D. M. E. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2008.06.014 · Cited by 41
Chik, K. ‐., Li, C. K., Pk, C., Mm, S., Lee, V., Tam, J., & Pm, Y. (2004) · PubMed · Cited by 38
D’Agostini, C., Palamara, A. T., Favalli, C., Sivilia, M., Febbraro, G., Buè, C., & Garaci, E. (1996) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(96)00002-1 · Cited by 24
Higgs, E. S., Hayden, F. G., Chotpitayasunondh, T., Whitworth, J., & Farrar, J. (2007) · Antiviral Research · doi:10.1016/j.antiviral.2007.10.008 · Cited by 23
Self-citationChak, W.-L., Wong, F. K.-M., Ng, Y. W., Wong, H.-S., Choi, K.-S., Chau, K., Tiu, S.-C., & Li, C. S. (2004) · Hong Kong Journal of Nephrology · doi:10.1016/s1561-5413(09)60167-8 · Cited by 12
Cited by
Krammer, F., Smith, G. J. D., Fouchier, R. A. M., Peiris, M., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J., Webster, R. G., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0002-y · Cited by 1,570
Harper, S. A., Bradley, J. S., Englund, J. A., File, T. M., Gravenstein, S., Hayden, F. G., McGeer, A. J., Neuzil, K. M., Pavia, A. T., Tapper, M. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598513 · Cited by 647
Self-citationInfluenza Hemagglutinin and Neuraminidase Membrane Glycoproteins
Gamblin, S. J., & Skehel, J. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.129809 · Cited by 638
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Heneghan, C. J., Hama, R., & Thompson, M. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub3 · Cited by 594
Neuraminidase inhibitors for preventing and treating influenza in adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Hama, R., Thompson, M. J., Spencer, E. A., Onakpoya, I. J., Mahtani, K. R., Nunan, D., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub4 · Cited by 382
Metadata
- Authors
- Hayden, F.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01
- Volume
- 48
- Issue
- S1
- Pages
- S3-S13
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2125529503
- Cited by
- 256
- References
- 60
- FWCI
- 23.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.